Author

Andreana Robertson

Institution: Novavax (United States)

Observed institutions: University of Maryland, Baltimore, Novavax (United States)

ORCID: 0000-0002-5125-9296

Observed ORCID: 0000-0002-5125-9296

OpenAlex ID: A5102739967

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

2020 · Cheryl Keech, Gary Albert, et al. · New England Journal of Medicine · 1,156

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

2021 · Vivek Shinde, Sutika Bhikha, et al. · New England Journal of Medicine · 620

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

2021 · Neil Formica, Raburn Mallory, et al. · PLoS Medicine · 105

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

2022 · Raburn M Mallory, Neil Formica, et al. · The Lancet Infectious Diseases · 96

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

2022 · Paul T Heath, Eva P Galiza, et al. · Clinical Infectious Diseases · 71

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

2022 · Shabir A Madhi, Dhayendre Moodley, et al. · The Lancet HIV · 62

Works count: 6

Citation count: 2,110

H-index: 6

I10-index: 6